WO2026133294 - PD-1/GITR MULTISPECIFIC BINDING POLYPEPTIDES AND USES THEREOF

National phase entry is expected:
Publication Number WO/2026/133294
Publication Date 25.06.2026
International Application No. PCT/IB2025/063274
International Filing Date 19.12.2025
Title **
[English] PD-1/GITR MULTISPECIFIC BINDING POLYPEPTIDES AND USES THEREOF
[French] POLYPEPTIDES DE LIAISON MULTISPÉCIFIQUES PD-1/GITR ET LEURS UTILISATIONS
Applicants **
SANOFI
ABLYNX N.V.
Inventors
BAUDHUIN, Jérémy
BEIL, Christian
LANGE, Christian
LI, Sandra
ÖZGÜR BRÜDERLE, Sevim
SARMIENTO, Natalia
SASSOON, Ingrid
WEIL, Sandra
Priority Data
24307255.0   20.12.2024   EP
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting3214
EPO Filing, Examination, Granting19365
Japan Filing, Examination, Granting2735
South Korea Filing, Examination, Granting3127
USA Filing, Examination, Granting12190
MasterCard Visa
Total: 40,631
Contact Us
Abstract[English] The present disclosure provides multispecific (e.g., bispecific) binding proteins with binding specificity to TNFR superfamily receptor (TNFRSF) and an immune checkpoint protein.[French] La présente divulgation concerne des protéines de liaison multispécifiques (par exemple, bispécifiques) présentant une spécificité de liaison pour un récepteur de la superfamille des TNFR (TNFRSF) et une protéine de point de contrôle immunitaire.